These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 3054671)

  • 1. Activity of epirubicin and dibromodulcitol in advanced breast cancer. Results of the South-East European Oncology Group Study.
    Eckhardt S; Juhos E; Hindy I; Jelic S; Koza I; László G; Mechl Z; Nagykálnay T; Pawlicki M; Schoket Z
    Oncology; 1988; 45(6):409-12. PubMed ID: 3054671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of epirubicin in combination chemotherapy of advanced ovarian cancer. Results of the South-East European Oncology Group (SEEOG) Study.
    Eckhardt S; Szántó J; Cerar O; Chylak V; Hernádi Z; Hindy I; József S; Juhos E; Kolaric K; Kopecny J
    Oncology; 1987; 44(2):69-72. PubMed ID: 3554083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of oral idarubicin plus dibromodulcitol in advanced breast cancer.
    Smith DB; Howell A
    Eur J Cancer Clin Oncol; 1989 Jan; 25(1):141-3. PubMed ID: 2920761
    [No Abstract]   [Full Text] [Related]  

  • 4. Dibromodulcitol, mitomycin C and vinblastine (DMV) chemotherapy in advanced breast cancer.
    Howell A; Morrison JM; Bramwell VH; Harland RN; Moneypenny IJ
    Eur J Cancer Clin Oncol; 1984 Jul; 20(7):873-6. PubMed ID: 6540188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy of cervix cancer with mitolactol (dibromodulcitol, NSC 104800) and cisplatin. A phase I study of the Gynecologic Oncology Group.
    Omura GA; Hubbard JL; Hatch KD; Schlaerth JB; Blessing JA
    Am J Clin Oncol; 1992 Jun; 15(3):185-7. PubMed ID: 1590269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of adriamycin and dibromodulcitol in metastatic breast carcinoma.
    Tormey DC; Simon R; Falkson G; Bull J; Band P; Perlin E; Blom J
    Cancer Res; 1977 Feb; 37(2):529-34. PubMed ID: 832277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitomycin and tamoxifen versus mitolactol, doxorubicin, and tamoxifen in patients with previously treated breast cancer.
    Falkson G; Gelman RS; Tormey DC; Taylor SG; Falkson HC
    Cancer Treat Rep; 1985; 69(7-8):755-60. PubMed ID: 4016786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose epirubicin in combination with cyclophosphamide (HD-EC) in advanced breast cancer: final results of a dose finding study and phase II trial.
    Marschner N; Nagel GA; Beyer JH; Adler M; Ammon A
    Onkologie; 1990 Aug; 13(4):272-8. PubMed ID: 2234780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of epirubicin plus docetaxel as neoadjuvant chemotherapy in locally-advanced breast cancer.
    Hirano A; Shimizu T; Imamura H; Watanabe O; Kinoshita J; Okabe T; Kimura K; Kamimura M; Domoto K; Aiba M; Ogawa K
    Anticancer Res; 2006; 26(1B):581-4. PubMed ID: 16739324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical evaluation of effects from neoadjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer--comparative study of treatment with 2 and 4 cycles].
    Tong F; Yang D; Zhou B; Cao Y; Liu P; Liu H; Wang S; Qiao X; Zhang J
    Gan To Kagaku Ryoho; 2004 Feb; 31(2):205-8. PubMed ID: 14997752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclophosphamide, epirubicin and cisplatin (CEP) in advanced breast cancer: preliminary results.
    Zaniboni A; Marpicati P; Simoncini E; Gorni F; Ferrari V; Raffaglio E; Garattini MP; Marini G
    Anticancer Res; 1987; 7(4B):813-5. PubMed ID: 3479042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.
    J Clin Oncol; 1988 Apr; 6(4):679-88. PubMed ID: 2895801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group.
    Fountzilas G; Papadimitriou C; Dafni U; Bafaloukos D; Skarlos D; Moulopoulos LA; Razis E; Kalofonos HP; Aravantinos G; Briassoulis E; Papakostas P; Abela K; Gogas E; Kosmidis P; Pavlidis N; Dimopoulos MA
    J Clin Oncol; 2001 Apr; 19(8):2232-9. PubMed ID: 11304776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial.
    ; Ambrosini G; Balli M; Garusi G; Demicheli R; Jirillo A; Bonciarelli G; Bruscagnin G; Fila G; Bumma C; Lacroix F; Buzzi F; Di Costanzo F; Padalino D; Brugia M; Calabresi F; Natali M; Cartei G; Chiesa G; Blasina B; Ciambellotti E; Moro G; D'Aquino S; Altavilla G; Adamo V; De Maria D; Falchi AM; Bertoncelli P; Farris A; Fiorentino M; Fornasiero A; Fosser V; Daniele O; Foggi CM; Speranza GB; Sartori S; Camilluzzi E; Gallo L; Poggio R; Secondo V; Gambi A; Grignani F; Capodicasa E; Lopez M; Papaldo P; Di Lauro L; Vici P; Marenco G; Folco U; Bonanni F; Marsilio P; Palazzotto G; Di Carlo A; Cusimano MP; Pastorino G; Puccetti C; Giusto M; Rausa L; Gebbia N; Palmeri S; D'Alessandro N; Saccani F; Becchi G; Schieppati G; Spinelli I; Tagliagambe A; Tonato M; Minotti V; Ardia A; Viaro D; De Micheli P; Zingali G; Sacchetti G; Intini C
    J Clin Oncol; 1988 Jun; 6(6):976-82. PubMed ID: 2897433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of dibromodulcitol and BCNU in metastatic malignant melanoma.
    Clamon G; Sinkey C; Jochimsen P
    Am J Clin Oncol; 1985 Jun; 8(3):244-6. PubMed ID: 4050743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial.
    Focan C; Andrien JM; Closon MT; Dicato M; Driesschaert P; Focan-Henrard D; Lemaire M; Lobelle JP; Longree L; Ries F
    J Clin Oncol; 1993 Jul; 11(7):1253-63. PubMed ID: 8315422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial.
    Huang L; Chen S; Yang W; Xu B; Huang T; Yang H; Zheng H; Wang Y; Song E; Zhang J; Cui S; Pang D; Tang L; Lei Y; Geng C; Shao Z
    Oncotarget; 2015 Jul; 6(21):18683-92. PubMed ID: 26084292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ifosfamide, mesna and epirubicin as second-line chemotherapy in advanced breast cancer.
    Kiraz S; Baltali E; Güler N; Barista I; Benekli M; Celik I; Güllü IH; Kars A; Tekuzman G; Firat D
    J Chemother; 1996 Aug; 8(4):310-4. PubMed ID: 8873839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
    Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trial.
    Focan C; Graas MP; Beauduin M; Canon JL; Salmon JP; Jerusalem G; Focan-Henrard D; Lobelle JP; Schallier D
    Anticancer Res; 2005; 25(2B):1211-7. PubMed ID: 15865068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.